EBR Systems Receives Final Approval for NTAP Reimbursement; Shares Up 7%
MT Newswires Live
Aug 05
EBR Systems (ASX:EBR) said the US Centers for Medicare & Medicaid Services confirmed approval for its Wireless Stimulation Endocardially for Cardiac Resynchronization Therapy (WiSE CRT) System under the New Technology Add-On Payment (NTAP) scheme for Medicare inpatients, according to a Tuesday filing with the Australian bourse.
The confirmation ensures a maximum reimbursement rate of up to $41,145, based on an average WiSE selling price of $63,300, in addition to Diagnosis Related Group payments for procedure and device costs, the filing said.
The NTAP reimbursement will remain in effect for three years, according to the filing.
Shares rose more than 7% in morning trade on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.